CWBR News and Press, CohBar Inc. From 08/26/20

CohBar (NASDAQ: CWBR ) plunged in trade post it priced earlier announced underwritten public offering of 12.3M units at $1.22/unit; each unit consists of one share and one warrant to purchase 0.75 of a share at a per share exercise price of $1.44. More news on: CohBar, Inc., Healthca...

MENLO PARK, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the pricing of an underwr...

Garrett Motion (NYSE: GTX )   -24%  as the company explores "alternatives for addressing its previously disclosed balance sheet concerns ." More news on: Garrett Motion Inc., XpresSpa Group, Inc., CohBar, Inc., Stocks on the move, , Read more ...

Tricida suffers setback on Veverimer front Tricida Inc. ( TCDA ) reported that the FDA has given a Complete Response Letter to the company for its application pertaining to Veverimer. The New Drug Application for the drug candidate was being reviewed under the Accelerated Approval Progra...

CohBar (NASDAQ: CWBR ) announces  a proposed underwritten public offering of units consisting of one common share and one warrant to purchase 0.75 of a share within 5 years. Price, terms and volume not yet disclosed. More news on: CohBar, Inc., Healthcare stocks news, , Read ...

MENLO PARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced a proposed underwritten p...

Dosing is underway for CohBar's ( CWBR +1.4% ) lead program, CB4211 in Phase 1b part of its Phase 1a/1b trial for nonalcoholic steatohepatitis (NASH) and obesity. More news on: CohBar, Inc., Healthcare stocks news, Read more ...

MENLO PARK, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the first subjects have been dosed with CB4211 in ...

The following slide deck was published by CohBar, Inc. in conjunction with their 2020 Q2 earnings Read more ...

CohBar, Inc. (CWBR) Q2 2020 Earnings Conference Call August 13, 2020, 05:00 PM ET Company Participants Jordyn Tarazi - Director of IR Steve Engle - CEO Ken Cundy - Chief Scientific Officer Jeff Biunno - CFO Conference Call Participants Kumar Raja - Brookline Capital Marke...